Clinical Trial Update: Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer [NA]

View source ↗

Summary

A clinical trial evaluating daily adaptive radiation therapy for Stage III non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Varian, a Siemens Healthineers Company | Conditions: Stage III Non-small Cell Lung Cancer | NA | Status: WITHDRAWN